Total Payments
$1.5M
2024 Payments
$191,933
Companies
60
Transactions
1,754
Medicare Patients
1,279
Medicare Billing
$234,018
Payment Breakdown by Category
Other$1.2M (78.1%)
Consulting$147,363 (9.6%)
Travel$137,853 (9.0%)
Food & Beverage$42,838 (2.8%)
Research$7,730 (0.5%)
Education$433.98 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 430 | 75.7% |
| Consulting Fee | $147,363 | 85 | 9.6% |
| Travel and Lodging | $137,853 | 546 | 9.0% |
| Food and Beverage | $42,838 | 659 | 2.8% |
| Honoraria | $27,090 | 14 | 1.8% |
| Unspecified | $7,730 | 4 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,607 | 6 | 0.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $750.00 | 1 | 0.0% |
| Education | $433.98 | 9 | 0.0% |
Payments by Type
General
$1.5M
1,750 transactions
Research
$7,730
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $300,745 | 365 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $186,210 | 134 | $0 (2024) |
| ABBVIE INC. | $148,348 | 168 | $0 (2024) |
| Amgen Inc. | $132,376 | 159 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $123,426 | 129 | $0 (2024) |
| Celgene Corporation | $114,098 | 117 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $79,017 | 100 | $0 (2024) |
| GENZYME CORPORATION | $69,095 | 59 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $61,869 | 63 | $0 (2022) |
| Pharmacyclics LLC, An AbbVie Company | $61,123 | 100 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $191,933 | 193 | Incyte Corporation ($48,745) |
| 2023 | $237,975 | 260 | E.R. Squibb & Sons, L.L.C. ($49,763) |
| 2022 | $307,028 | 321 | E.R. Squibb & Sons, L.L.C. ($112,094) |
| 2021 | $166,093 | 164 | Incyte Corporation ($51,193) |
| 2020 | $96,913 | 98 | Incyte Corporation ($30,417) |
| 2019 | $140,923 | 188 | Incyte Corporation ($32,558) |
| 2018 | $144,941 | 192 | Amgen Inc. ($40,888) |
| 2017 | $246,622 | 338 | Amgen Inc. ($43,739) |
All Payment Transactions
1,754 individual payment records from CMS Open Payments — Page 1 of 71
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,176.00 | General |
| Category: Hematology | ||||||
| 12/18/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | Cash or cash equivalent | $13.44 | General |
| Category: Oncology | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $34.22 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Travel and Lodging | Cash or cash equivalent | $24.12 | General |
| Category: Hematology | ||||||
| 12/12/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/09/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $115.30 | General |
| Category: Oncology | ||||||
| 12/08/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $75.02 | General |
| Category: Oncology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $124.05 | General |
| Category: Hematology | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,350.00 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $70.00 | General |
| Category: Hematology/Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,625.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Consulting Fee | Cash or cash equivalent | $1,880.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $126.99 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | Cash or cash equivalent | $49.00 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Amgen Inc. | Blincyto (Biological) | Travel and Lodging | Cash or cash equivalent | $154.10 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $31.39 | General |
| Category: Oncology | ||||||
| 11/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $23.99 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $17.03 | General |
| Category: Hematology | ||||||
| 11/05/2024 | ABBVIE INC. | EPKINLY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Pre- versus Post-VIALE-A Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed AML from a Predominantly US Community Setting | F. Hoffmann-La Roche AG | $3,343 | 1 |
| VENETOCLAX AND HYPOMETHYLATING AGENTS AS FIRST-LINE TREATMENT IN NEWLY DIAGNOSED PATIENTS WITH AML IN A PREDOMINATELY COMMUNITY SETTING IN THE US | F. Hoffmann-La Roche AG | $2,995 | 1 |
| USE OF BISPECIFIC ANTIBODIES (BsAbs) IN COMMUNITY PRACTICES: MULTIDISCIPLINARY PERSPECTIVES ON DEVELOPING LOGISTICS AND WORKFLOW FOR CYTOKINE RELEASE SYNDROME (CRS) MANAGEMENT | F. Hoffmann-La Roche AG | $896.11 | 1 |
| REAL WORLD TREATMENT PATTERNS AND OUTCOMES OF VENETOCLAX VEN AND HYPOMETHYLATING AGENTS HMA IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA AML IN THE UNITED STATES | F. Hoffmann-La Roche AG | $495.09 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 501 | 3,747 | $189,209 | $89,911 |
| 2022 | 11 | 484 | 3,002 | $173,351 | $79,523 |
| 2021 | 11 | 294 | 2,080 | $126,153 | $64,585 |
Total Patients
1,279
Total Services
8,829
Medicare Billing
$234,018
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 51 | 368 | $103,976 | $47,027 | 45.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 35 | 158 | $29,704 | $13,903 | 46.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 51 | 520 | $9,360 | $5,382 | 57.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 51 | 505 | $7,070 | $3,843 | 54.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 27 | $7,398 | $3,486 | 47.1% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 50 | 506 | $5,566 | $2,996 | 53.8% |
| G0316 | Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 2023 | 29 | 130 | $6,630 | $2,951 | 44.5% |
| 84100 | Phosphate level | Office | 2023 | 50 | 509 | $4,581 | $2,367 | 51.7% |
| 83735 | Magnesium level | Office | 2023 | 41 | 340 | $4,080 | $2,234 | 54.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 42 | 249 | $3,726 | $2,089 | 56.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 19 | 20 | $3,600 | $1,698 | 47.2% |
| 82248 | Bilirubin level, direct | Office | 2023 | 28 | 198 | $1,782 | $974.16 | 54.7% |
| 84550 | Uric acid level, blood | Office | 2023 | 30 | 217 | $1,736 | $961.31 | 55.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 49 | 274 | $81,553 | $35,445 | 43.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 44 | 308 | $50,976 | $23,332 | 45.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 32 | 38 | $12,272 | $5,226 | 42.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 52 | 398 | $7,164 | $4,155 | 58.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 52 | 403 | $5,642 | $3,095 | 54.9% |
| 83735 | Magnesium level | Office | 2022 | 51 | 387 | $4,830 | $2,560 | 53.0% |
| 84100 | Phosphate level | Office | 2022 | 51 | 387 | $3,483 | $1,814 | 52.1% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2022 | 46 | 289 | $3,365 | $1,714 | 50.9% |
| 82248 | Bilirubin level, direct | Office | 2022 | 33 | 186 | $1,674 | $922.62 | 55.1% |
| 84550 | Uric acid level, blood | Office | 2022 | 33 | 188 | $1,504 | $839.39 | 55.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 41 | 144 | $888.00 | $418.95 | 47.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 36 | 211 | $56,970 | $28,511 | 50.0% |
About Dr. Jonathan Abbas, MD
Dr. Jonathan Abbas, MD is a Hematology & Oncology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1316145253.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Abbas, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $191,933 received in 2024. These payments were reported across 1,754 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.2M).
As a Medicare-enrolled provider, Abbas has provided services to 1,279 Medicare beneficiaries, totaling 8,829 services with total Medicare billing of $234,018. Data is available for 3 years (2021–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Nashville, TN
- Active Since 07/03/2007
- Last Updated 09/23/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1316145253
Products in Payments
- JAKAFI (Drug) $226,889
- VYXEOS (Drug) $110,036
- VENCLEXTA (Drug) $101,837
- ONUREG (Drug) $100,246
- DARZALEX (Biological) $95,437
- REBLOZYL (Biological) $83,159
- Blincyto (Biological) $63,661
- Kyprolis (Biological) $63,058
- MONJUVI (Drug) $62,758
- TIBSOVO (Drug) $48,637
- RYDAPT (Drug) $48,322
- Imbruvica (Drug) $46,413
- SARCLISA (Biological) $45,207
- Revlimid (Drug) $43,587
- EPKINLY (Drug) $38,797
- Pomalyst (Drug) $37,686
- ICLUSIG (Drug) $34,720
- Epkinly (Drug) $29,209
- IMBRUVICA (Drug) $26,740
- ELITEK (Drug) $23,926
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Nashville
Kent Shih, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Alan Tan, M.d, M.D
Hematology & Oncology — Payments: $1.0M
Hematology & Oncology $1.0M
Brian Rini, Md, MD
Hematology & Oncology — Payments: $685,999
Hematology & Oncology $685,999
Jesus Berdeja, M.d, M.D
Hematology & Oncology — Payments: $572,989
Hematology & Oncology $572,989
Dr. Krish Patel, M.d, M.D
Hematology & Oncology — Payments: $568,657
Hematology & Oncology $568,657
Dr. Robert Cornell, M.d, M.D
Hematology & Oncology — Payments: $564,553
Hematology & Oncology $564,553